When Launched, Gene Therapy Roctavian Will Be Administered Mainly In 340B-Eligible Treatment Centers, Where It Will Be Substantially Discounted In Price

The high list prices of gene therapies command the media’s attention and that of policymakers and payers. Late last year, the Food and Drug Administration (FDA) approved the world’s first gene therapy for severe and moderately severe hemophilia B; Hemgenix…